for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aduro BioTech Inc

ADRO.OQ

Latest Trade

1.02USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.92

 - 

6.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.02
Open
--
Volume
--
3M AVG Volume
9.45
Today's High
--
Today's Low
--
52 Week High
6.94
52 Week Low
0.92
Shares Out (MIL)
80.14
Market Cap (MIL)
81.74
Forward P/E
-1.06
Dividend (Yield %)
--

Latest Developments

More

Aduro Biotech Says James Welch, Interim CFO Notified Co Of His Intent To Resign

Aduro Biotech Posts Q2 Loss Per Share Of $0.23

Aduro Biotech And Novartis Present Results From Ongoing Phase 1B Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aduro BioTech Inc

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.

Industry

Biotechnology & Drugs

Contact Info

740 Heinz Ave

+1.510.8484400

http://www.aduro.com/

Executive Leadership

Stephen T. Isaacs

Chairman of the Board, President and Chief Executive Officer

Celeste S. Ferber

Senior Vice President, General Counsel, Secretary

Blaine E. Templeman

Chief Administrative Officer and Chief Legal Officer

Andrea van Elsas

Chief Scientific Officer

Daniel Hoth

Interim Chief Medical Officer

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.400

2017

-1.260

2018

-1.210

2019(E)

-0.960
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.58
Price To Book (MRQ)
0.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-27.40
Return on Equity (TTM)
-24.84

Latest News

Latest News

BRIEF-Aduro Biotech And Novartis Present Results From Ongoing Phase 1B Study

* ADURO BIOTECH AND NOVARTIS PRESENT RESULTS FROM ONGOING PHASE 1B STUDY OF STING AGONIST ADU-S100 (MIW815) IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY SPARTALIZUMAB (PDR001) IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS

BRIEF-Aduro Biotech Q1 Loss Per Share $0.28

* Q1 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Aduro Announces Milestone Achieved Under Merck Collaboration

* ADURO ANNOUNCES MILESTONE ACHIEVED UNDER MERCK COLLABORATION FOR INITIATION OF ANTI-CD27 PHASE I TRIAL IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Promotes Hans Van Eenennaam In Its Europe Unit

* ADURO BIOTECH APPOINTS HANS VAN EENENNAAM EXECUTIVE VICE PRESIDENT ANTIBODY RESEARCH AND SITE HEAD, ADURO BIOTECH EUROPE Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Q4 Loss Per Share $0.34

* ADURO BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Aduro Biotech Announces Management Changes

* ADURO BIOTECH INC - JENNIFER LEW HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER

BRIEF-Aduro Biotech Expands Leading Intellectual Property Position In STING Field With Newly Issued Patent

* ADURO BIOTECH EXPANDS LEADING INTELLECTUAL PROPERTY POSITION IN STING FIELD WITH NEWLY ISSUED PATENT Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech Provides Update On CRS-207 Programs

* COMPANY HAS DETERMINED THAT IT WILL NOT CONTINUE ADVANCEMENT OF CRS-207

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

* Aduro Biotech Inc - announced data from preclinical studies with ADU-1604, company's humanized anti-CTLA-4 monoclonal antibody

BRIEF-Aduro Biotech reports Q3 loss per share $0.33

* Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S

BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD

* Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology

BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas

* Aduro Biotech announces advancement of ADU-S100 into global combination trial with PDR001 for the treatment of solid tumors and lymphomas

BRIEF-HitGen and Aduro Enter Research Collaboration

* Entered into a multi-target multi-year collaboration with Aduro Biotech Inc

BRIEF-Aduro Biotech files for resale of up to 25.41 mln shares of common stock by the selling stockholders

* Aduro Biotech Inc files for resale of up to 25.41 million shares of co's common stock by the selling stockholders - sec filing Source text - http://bit.ly/2v0rE5d Further company coverage:

BRIEF-Aduro Biotech files for mixed shelf of upto $300 mln

* Aduro Biotech Inc files for mixed shelf of upto $300 million - sec filing Source text - http://bit.ly/2w7SKYi Further company coverage:

BRIEF-Aduro Biotech Q2 loss per share $0.27

* Aduro Biotech reports second quarter 2017 financial results

BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck

* Aduro Biotech- $2.0 million milestone payment under worldwide licensing deal with merck for work supporting preparation of ind for anti-cd27 antibody

BRIEF-Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda

* Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda® (pembrolizumab) for the treatment of patients with previously treated malignant pleural mesothelioma Source text for Eikon: Further company coverage:

BRIEF-Aduro Biotech announces clinical collaboration with Merck

* Aduro Biotech announces clinical collaboration with Merck to evaluate combination of Aduro's CRS-207 with Merck's Keytruda for treatment of Mesothelioma

BRIEF-Aduro Biotech reports revenue for Q1 of $3.8 million

* Q1 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up